A Plasmart Initiative
Curing All Human Blood Factor Mutations
Permanently. Precisely. Across generations.
Permanently. Precisely. Across generations.
Plasmart is building the genomic foundation to cure hereditary blood factor deficiencies — mapping every variant across Factor I through XIII, archiving family genomes, and preparing the data that future gene therapies will need.
Bleeding disorders are often overlooked and underdiagnosed. Despite affecting millions worldwide, inherited coagulation factor deficiencies receive far less research focus than conditions of similar prevalence. As a result of lower awareness, increased time to diagnosis, and a lack of treatment innovation, many people remain undiagnosed or improperly treated.
Current treatments have significant limitations. Many patients rely on frequent IV infusions of clotting factor concentrates. Some miss school or work due to bleeding episodes or treatment schedules. Women with bleeding disorders face heavy menstrual bleeding and dangerous postpartum hemorrhage. A single deficiency in any of the thirteen coagulation factors can mean a lifetime of medical intervention.
Hereditary deficiencies in any of these proteins cause bleeding disorders. Whole-genome sequencing covers them all — every exon, every known pathogenic variant.
| Gene | Condition | 30× WGS | Genotyping |
|---|---|---|---|
| F8 | Hemophilia A | 186,561 | 3 |
| F9 | Hemophilia B | 33,784 | 0 |
| VWF | von Willebrand Disease | 179,426 | 6 |
| F5 | Factor V Deficiency | 71,122 | 1 |
| F7 | Factor VII Deficiency | 31,330 | 0 |
| F11 | Factor XI Deficiency | 55,188 | 0 |
| F13A1 | Factor XIII Deficiency | 66,994 | 0 |
Variant counts per gene. Consumer genotyping checks markers; 30× whole-genome sequencing reads the entire gene. Data from Sequencing.com.
By analyzing parental and child DNA, we seek to pioneer precise interventions that correct underlying mutations at their source — so children, grandchildren, and generations to come can live free from the burden of bleeding disorders.
The genome does not lie. A single nucleotide change in the F8 gene — one letter out of 3.2 billion — can cause Hemophilia A. Current genotyping arrays check less than 0.1% of the genome. They miss the vast majority of pathogenic variants in coagulation factor genes.
30× whole-genome sequencing reads everything: every exon, every intron, every regulatory region. It produces the raw FASTQ, aligned BAM, and variant-called VCF files that researchers and clinicians need.
Data is the foundation of future cures. Gene therapy for Hemophilia A and B is already in clinical trials. But these therapies need precise variant data to work — they must know exactly what is broken before they can fix it.
Plasmart's Sequence Me program archives complete family genomes today so that when curative therapies become available, families will have the data ready. No re-sequencing. No delays. Just the information needed to act.
White-glove whole-genome sequencing and archival for families affected by hereditary blood factor deficiencies. From intake to delivery in 10–14 weeks.
Submit family information. Privacy-first naming using initials and birth year.
We order 30× WGS kits from Sequencing.com and ship to your family.
Saliva or cheek swab at home. Activate online, return prepaid.
30× whole-genome sequencing. 6–10 weeks with status updates.
Organized, checksummed, packaged on encrypted media. Delivered to your door.
Already have whole-genome data? Bring-your-own-data archival starts at $50.
Every genome sequenced today is a family prepared for tomorrow's cures.
Get Started with Sequence MeSequence Me is a nonclinical genome data preservation and concierge service. We do not provide medical advice, diagnosis, treatment, or genetic counseling. Sequencing is performed by Sequencing.com. Always consult qualified medical professionals for health decisions.
Your genomic data is never sold, shared, or used for research without explicit consent. Privacy-first naming. Encrypted delivery. Your files go to you and nowhere else.
References
1. Centers for Disease Control and Prevention. What is Von Willebrand Disease? April 1, 2021.
2. Mannucci PM, Tuddenham EGD. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
3. Srivastava A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1-158.
4. Pipe SW. Gene therapy for hemophilia. Pediatr Blood Cancer. 2018;65(2):e26863.
5. James PD, et al. von Willebrand disease: advances in pathophysiology and management. Thromb Haemost. 2017;117(7):1239-1247.
6. Sequencing.com. Whole Genome Sequencing: 30× Coverage. 2025.